Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-25 @ 1:27 AM
Ignite Modification Date:
2025-12-25 @ 11:38 PM
NCT ID:
NCT02558894
Pre Assignment Details:
65 patients were randomised to receive investigational product (IP) and 64 received treatment. One randomised patient in the durvalumab monotherapy arm was withdrawn prior to receiving any IP but was still included in the full analysis set (FAS) which was used for participant flow and baseline analysis.
Recruitment Details:
First patient enrolled: 16 Nov 2015; Part A data cut-off: 26 May 2017. The study contained a Part B which was not opened; only Part A was conducted.
Study assessed efficacy of durvalumab (MEDI4736) + tremelimumab combination therapy compared to durvalumab (MEDI4736) monotherapy.
Study performed at 21 sites in 6 countries.
Study:
NCT02558894
Study Brief:
Results Section:
NCT02558894